Non-Viral Delivery of the CRISPR/Cas System: DNA Versus RNA Versus RNP

    January 2022 in “ Biomaterials Science ”
    Yi Lin, Ernst Wagner, Ulrich Lächelt
    Studysummary This article reviews CRISPR/Cas system delivery methods for genome editing and highlights RNA's promise in non-viral in vivo applications but reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pubs.rsc.org →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Ultrasound-Activated Particles as CRISPR/Cas9 Delivery System for Androgenic Alopecia Therapy Biomaterials · 2019

    Related research 1

    1. Non-Viral Delivery of the CRISPR/Cas System: DNA Versus RNA Versus RNP Biomaterials Science · 2022